Solveeit Logo

Question

Question: Who discovered mycoplasma? A) Nocard and Roux B) Alexander Fleming C) Kohler and Milstein D)...

Who discovered mycoplasma?
A) Nocard and Roux
B) Alexander Fleming
C) Kohler and Milstein
D) Both A and B

Explanation

Solution

Mycoplasma is the smallest cell of 0.3 um length. It is a pathogen that basically causes the disease Mycoplasma pneumonia, a form of typical bacteria. Considering its discovery, keep in mind that it was isolated from the bovine.

Complete answer:
Mycoplasma was a great discovery in 1898. Before talking about the discovery let us talk about its history. Symptoms of pneumonia were first discovered by Greek physicians in 460 BC. Several pathogens are found in humans, including M. Pneumonia, which can cause "walking "pneumonia and other respiratory diseases.

M.pneumonia was first isolated from the tissue culture from the sputum of the patient, typical pneumonia as Eaton agent. It was a leading cause of community-acquired pneumonia. It has been known for over 50 years as a pleuropneumonia- like an organism (PPLO) in many organisms. Isolation of first pneumonia was the bovine pleuropneumonia agent, known as M. mycosis over past many years which was later reported by Nocard and Roux.

Lets us infer about the options given above-
- Alexander Fleming is a versatile Scottish physician who is known for the discovery of penicillin. It was discovered in 1929 which was later named as benzylpenicillin.
- Kohler and Milstein are known for monoclonal antibodies discovery produced by hybridoma technology. They immortalized the antibodies producing cells by fusing them with tumour cells. This method was used for the production of monoclonal antibodies in large numbers.

The answer to the above question is A, that is Nocard and Roux in 1898. It is one of the leading communities that acquired pneumonia.

Note: Mycoplasma Pneumonia bacteria is the smallest bacteria which was earlier put into the category of fungi and bacteria but later it was considered as a virus. It is mainly characterised by the absence of peptidoglycan cell wall and resulting resistance to many antibacterial agents. The persistence of M. pneumonia infections even after it is being treated.